Anti-BCMA CAR T-Cell Therapy Active in Heavily Pretreated Myeloma – Cancer Network
Medical Xpress |
Anti-BCMA CAR T-Cell Therapy Active in Heavily Pretreated Myeloma
Cancer Network A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I (abstract 740) study presented at the … CAR T, immunotherapy bring new hope for multiple myeloma patientsMedical Xpress ‘Unheard of’ responses to bluebird CAR–T therapy seen in myeloma studyReuters #ASH17: The BCMA-targeted CAR–T bb2121 from bluebird and Celgene takes a star turn in the spotlightEndpoints News |
|
ToolGen, Inc. Demonstrates Potential of CRISPR/cas9 Gene Editing to Overcome T-Cell Immunosuppression
GlobeNewswire (press release) SEOUL, South Korea, Dec. 11, 2017 (GLOBE NEWSWIRE) — ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced data demonstrating that the Company’s CRISPR/Cas9 gene editing platform can target and disrupt … |
Endpoints News |
#ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky
Endpoints News Following up on its impressive work on a new gene therapy for hemophilia B, Spark Therapeutics $ONCE has offered a peek at its cards on the early data from a separate program it has on hemophilia A. And it’s clear that there’s a lot of work to be done … ASH17: Spark gene therapy falls behind BioMarin in hemophiliaBioPharma Dive Gene Therapy Nearly Eliminates Hemophilia B Bleeding Episodes, Trial ShowsHemophilia News Today This Bull Is Sticking By Spark Therapeutics Inc (ONCE) and Its Novel …Smarter Analyst Zacks Investment Research –SEC.gov all 115 news articles » |